Sarah Jensen, MD
Dermatology · Festus, MONPI 1639119175
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $15,906 of the $22,198 with a category attached, or 71.7%. 33 manufacturers reported payments, led by UCB, Inc. at 26.1% of the total. Reporting peaked in 2024 at $7,106 and has fallen 62.7% since, to $2,648 in 2025. Among dermatology clinicians in MO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,041 payments — averaging $21.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$6K
- AbbVie$2K
- Amgen$2K
- Arcutis Biotherapeutics, Inc.$1K
- Johnson & Johnson$1K
- E.r. Squibb & Sons, L.L.C.$1K
- plus $8K from 27 others
What the payments were for
- Consulting fees$5,87326%
- Travel & lodging$150%
- Food & beverage$15,90672%
- Education$4042%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 50 | $5,802 |
| AbbVie(2 entities) | 170 | $2,382 |
| Amgen | 87 | $1,506 |
| Arcutis Biotherapeutics, Inc. | 42 | $1,476 |
| Johnson & Johnson | 92 | $1,423 |
| E.r. Squibb & Sons, L.L.C. | 60 | $1,129 |
| Regeneron Healthcare Solutions, Inc. | 34 | $733 |
| Dermavant Sciences, Inc. | 65 | $706 |
| Prugen, Inc. Pharmaceuticals | 52 | $685 |
| LEO Pharma Inc. | 91 | $671 |
| Galderma Laboratories, L.p. | 27 | $618 |
| Lilly USA, LLC | 30 | $589 |
| Mayne Pharma Commercial LLC | 79 | $547 |
| Sun Pharmaceutical Industries Inc. | 18 | $491 |
| Journey Medical Corporation | 14 | $437 |
| Boehringer Ingelheim | 5 | $412 |
| Sanofi | 17 | $381 |
| Organogenesis Inc. | 7 | $320 |
| Pfizer | 17 | $305 |
| Novartis | 18 | $283 |
| Almirall LLC | 12 | $278 |
| Kerecis Limited | 2 | $246 |
| Janssen Scientific Affairs, LLC | 1 | $124 |
| Bristol Myers Squibb | 17 | $119 |
| Incyte Corporation | 6 | $113 |
| Biofrontera Inc. | 6 | $92 |
| EPI Health, LLC | 4 | $83 |
| Organon | 6 | $56 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 4 | $56 |
| Mission Pharmacal Company | 3 | $44 |
| Genentech USA, Inc. | 2 | $38 |
| Strata Skin Sciences, Inc. | 2 | $37 |
| Merck | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$22,198 in reported general payments places this provider in the 90th percentile of 263 dermatology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 21 | $286,755 |
| OtezlaApremilast | 41 | $205,242 |
| RinvoqUpadacitinib | 12 | $77,480 |
| Fluorouracil | 91 | $5,761 |
| Clobetasol Propionate | 83 | $3,021 |
| Triamcinolone Acetonide | 181 | $2,790 |
| Metronidazole | 18 | $1,802 |
| Fluocinolone AcetonideFluocinolone/Shower Cap | 22 | $1,250 |
| Doxycycline Hyclate | 50 | $866 |
| Ketoconazole | 68 | $861 |
| Nystatin | 85 | $850 |
| Hydroxychloroquine Sulfate | 13 | $652 |
| Hydrocortisone | 85 | $573 |
| ValacyclovirValacyclovir Hcl | 27 | $521 |
| Clindamycin Phosphate | 18 | $451 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenOtezla | $1,506 | $205,24241 claims |
| AbbVieRinvoq | $2,382 | $77,48012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 263 dermatology providers in Missouri.
Other dermatology in Festus
- Brian KimSaint Louis$861K
- Elaine SiegfriedSaint Louis$856K
- Craig LeonardiSaint Louis$569K
- Jonathan CleaverKirksville$483K
- Mary GeorgeSaint Louis$400K
- David CleaverKirksville$371K
- Christy RaineyBranson$328K
- Charles MoonCape Girardeau$296K
- John DespainOsage Beach$289K
- Duane DilworthSaint Louis$288K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.